On 21 December 2024, Novo Nordisk announced that the US FDA has approved its Alhemo® (concizumab) injection as a once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes in adult and paediatric patients 12 years or age and older with haemophilia A or B with inhibitors. Alhemo® is the first subcutaneous injection treatment of its kind for this population.
In addition to the US, Alhemo® is currently approved in Australia, Japan, Switzerland and the EU, with specific indications varying by country.